NCT00112437View on ClinicalTrials.gov

A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)

PHASE2CompletedINTERVENTIONAL
Enrollment

399

Participants

Timeline

Start Date

June 24, 2005

Primary Completion Date

December 26, 2007

Study Completion Date

January 20, 2016

Conditions
Osteoporosis
Interventions
DRUG

Odanacatib

Odanacatib 3 mg, once weekly for 24 months

DRUG

Odanacatib

Odanacatib 10 mg, once weekly for 24 months

DRUG

Odanacatib

Odanacatib 25 mg, once weekly for 24 months

DRUG

Odanacatib

Odanacatib 50 mg, once weekly for 24 months

DIETARY_SUPPLEMENT

Vitamin D3

Vitamin D3, two 2800 IU weekly throughout the study

DIETARY_SUPPLEMENT

Calcium Carbonate

Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.

DRUG

Placebo

Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00112437 - A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004) | Biotech Hunter | Biotech Hunter